Phase I/II study of the hypoxia-activated prodrug PR104 in refractory/relapsed acute myeloid leukemia and acute lymphoblastic leukemia
Marina Konopleva(The University of Texas MD Anderson Cancer Center), Hagop Kantarjian(The University of Texas MD Anderson Cancer Center), Jörge E. Cortes(The University of Texas MD Anderson Cancer Center), Cecilia Arana Yi(Mayo Clinic Hospital), Stefan Faderl(The University of Texas MD Anderson Cancer Center), Yongchuan Gu(University of Auckland), Sergej Konoplev(The University of Texas MD Anderson Cancer Center), Deborah A. Thomas(The University of Texas MD Anderson Cancer Center), Elihu H. Estey(University of Washington), Andrew L. Coveler(University of Washington), Farhad Ravandi(The University of Texas MD Anderson Cancer Center), Michael Andreeff(The University of Texas MD Anderson Cancer Center), Tapan Kadia(The University of Texas MD Anderson Cancer Center), William R. Wilson(University of Auckland), Peter F. Thall(The University of Texas MD Anderson Cancer Center), Hongbo Lu(The University of Texas MD Anderson Cancer Center), Juliana Benito(The University of Texas MD Anderson Cancer Center), Jennie B. Feliu(The University of Texas MD Anderson Cancer Center), Gautam Borthakur(The University of Texas MD Anderson Cancer Center), Hoang Q. Nguyen(The University of Texas MD Anderson Cancer Center), John Gutheil, Caimiao Wei(Pfizer (United States)), Naval Daver(The University of Texas MD Anderson Cancer Center), Elias Jabbour(The University of Texas MD Anderson Cancer Center), Teresa J. Melink, Steven Kornblau(The University of Texas MD Anderson Cancer Center), Naveen Pemmaraju(The University of Texas MD Anderson Cancer Center), Carlos E. Bueso‐Ramos(The University of Texas MD Anderson Cancer Center)
Cited by 121
Related Papers
Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel
|Blood|2016|5.9k
Revised Recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia
|Journal of Clinical Oncology|2003|2.7k
International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data
|Blood|2022|2.7k
Hematologic and Cytogenetic Responses to Imatinib Mesylate in Chronic Myelogenous Leukemia
|New England Journal of Medicine|2002|2k